Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 24;36(9):125.
doi: 10.1007/s11095-019-2654-z.

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia

Kent T J Chen  1   2 , Roger Gilabert-Oriol  1 , Marcel B Bally  3   4   5   6 , Ada W Y Leung  1   7   8
Affiliations
Review

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia

Kent T J Chen et al. Pharm Res. .

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia that is becoming more prevalent particularly in the older (65 years of age or older) population. For decades, "7 + 3" remission induction therapy with cytarabine and an anthracycline, followed by consolidation therapy, has been the standard of care treatment for AML. This stagnancy in AML treatment has resulted in less than ideal treatment outcomes for AML patients, especially for elderly patients and those with unfavourable profiles. Over the past two years, six new therapeutic agents have received regulatory approval, suggesting that a number of obstacles to treating AML have been addressed and the treatment landscape for AML is finally changing. This review outlines the challenges and obstacles in treating AML and highlights the advances in AML treatment made in recent years, including Vyxeos®, midostaurin, gemtuzumab ozogamicin, and venetoclax, with particular emphasis on combination treatment strategies. We also discuss the potential utility of new combination products such as one that we call "EnFlaM", which comprises an encapsulated nanoformulation of flavopiridol and mitoxantrone. Finally, we provide a review on the immunotherapeutic landscape of AML, discussing yet another angle through which novel treatments can be designed to further improve treatment outcomes for AML patients.

Keywords: acute myeloid leukemia; immunotherapy; liposomes; nanotechnology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Most commonly found mutations in AML.
Fig. 2
Fig. 2
Progression of AML therapeutics over the years.
Fig. 3
Fig. 3
Immunotherapy strategies for AML treatment.
See this image and copyright information in PMC

References

    1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907. - PubMed
    1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062. - PubMed
    1. Szotkowski T., Rohon P., Zapletalova L., Sicova K., Hubacek J., Indrak K. Secondary acute myeloid leukemia – a single center experience. Neoplasma. 2010;57(2):170–178. - PubMed
    1. Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009;94(4):454–459. - PMC - PubMed
    1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016 Jul 1 6(7):e441. Pubmed Central PMCID: 5030376. - PMC - PubMed